The Best of Oncology West 2021 Conference highlights the top 3-4 most clinically relevant achievements of 2020 for several tumour sites. Faculty will be drawn from some of the most influential oncologists across Canada. The Conference is chaired by Dr. Sharlene Gill and Dr. Daniel Heng and will incorporate several multi-disciplinary event sessions addressing: radiation oncology, surgical oncology and supportive care.
• To discuss the pivotal oncology trials presented in the different disease sites
• To review the current standard of care for key malignancies
• To discuss the current controversies in the management of specific cancers
Registration will be complimentary for Healthcare professionals. Industry representatives (both sponsor and non-sponsor) can register by contacting Laura Davidson at firstname.lastname@example.org.
Dr. Sharlene Gill
Dr. Sharlene Gill is a Professor of Medicine at the University of British Columbia and Staff Oncologist at the BC Cancer Agency. She is a medical oncologist specializing in gastrointestinal (GI) malignancies. She received a Bachelor’s of Science in Pharmacy (Honors) and an MD (Doctor of Medicine) from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology. Dr. Gill subsequently completed a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Master’s of Public Health from the Harvard School of Public Health (Boston, MA) before returning to Vancouver, Canada where she is presently a Professor of Medicine at the University of British Columbia and staff oncologist at the BC Cancer Agency.
Dr. Daniel Heng
Dr. Heng is a Staff Medical Oncologist at the Tom Baker Cancer Center in Calgary, Alberta and a Clinical Associate Professor of Medicine at the University of Calgary. He received his MD from the University of Calgary and completed his internal medicine and medical oncology residencies at the University of British Columbia in Vancouver, BC. He was trained at the BC Cancer in Vancouver, Canada and then completed an Experimental Therapeutics fellowship at the Cleveland Clinic Taussig Cancer Institute. He received a Masters of Public Health from Harvard University. He is the Chair of the Genitourinary Tumor Group in Calgary and is the Chair of the International mRCC Consortium Database. He has a keen interest in outcomes, prognostic factors and clinical trials research in metastatic renal cell carcinoma and other genitourinary malignancies.
For more information, please send requests to Laura Davidson email@example.com.
|8:30 a.m. - 8:40 a.m. PST||Welcome Address by Chairs - Dr. Sharlene Gill & Dr. Daniel Heng|
|8:40 a.m. - 9:05 a.m. PST||GU Prostate - Dr. Kim Chi|
|9:05 a.m. - 9:30 a.m. PST||GU NOn-Prostate - Dr. Daniel Heng|
|9:30 a.m. - 9:55 a.m. PST||Gynecological Cancers - Dr. Aalok Kumar|
|9:55 a.m. - 10:05 a.m. PST||BREAK|
|10:05 a.m. - 10:30 a.m. PST||SBRT Update/Oligometastases - Dr. David Palma|
|10:30 a.m. - 10:55 a.m. PST||Lymphoma - Dr. Kerry Savage|
|10:55 a.m. - 11:20 a.m. PST||Lung Cancer - Dr. Ying Wang|
|11:20 a.m. - 11:50 a.m. PST||LUNCH BREAK|
|11:50 a.m. - 12:15 p.m. PST||Palliative Care - Dr. Jessica Simon|
|12:15 p.m. - 12:40 p.m. PST||GI Colorectal - Dr. Sharlene Gill|
|12:40 p.m. - 1:05 p.m. PST||GI Non-Colorectal - TBC|
|1:05 p.m. - 1:15 p.m. PST||BREAK|
|1:15 p.m. - 1:40 p.m. PST||Melanoma - Dr. Ralph Wong|
|1:40 p.m. - 2:05 p.m. PST||Breast Cancer - Dr. Nancy Nixon|
|2:05 p.m. - 2:15 p.m. PST||Closing Remarks by Chairs - Dr. Sharlene Gill & Dr. Daniel Heng|
For sponsorship-related inquiries, please contact Bernadette Gregoris, Director of Operations at firstname.lastname@example.org.